Press release
Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034
Cancer anorexia, often linked with cancer cachexia, is a debilitating condition characterized by loss of appetite, reduced food intake, and progressive weight loss in cancer patients. It is one of the most common and distressing cancer-related complications, affecting up to 80% of patients with advanced cancer. Beyond worsening quality of life, cancer anorexia contributes to poor treatment tolerance, faster disease progression, and higher mortality rates.Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71597
Managing cancer anorexia requires a multidisciplinary approach, including nutritional support, appetite stimulants, metabolic modulators, and psychological interventions. In recent years, pharmaceutical companies and research institutes have intensified efforts to develop novel drugs targeting the underlying metabolic and inflammatory pathways. With rising cancer prevalence worldwide, the global Cancer Anorexia Market is projected to expand steadily through 2034.
Market Overview
• Market Size 2024: USD 1.9 billion
• Forecast 2034: USD 3.5 billion
• CAGR (2024-2034): 6.3%
Growth is being driven by rising cancer incidence, better recognition of cachexia-anorexia syndromes, and expansion of supportive oncology care globally.
Key Growth Drivers
• Increasing prevalence of advanced cancers requiring supportive care.
• Rising awareness of cachexia management guidelines.
• Development of novel appetite stimulants and metabolic modulators.
• Growing integration of nutritional interventions in oncology care.
• Expanding palliative care services worldwide.
Key Challenges
• Lack of standardized global treatment guidelines.
• Limited efficacy of existing appetite stimulants (e.g., megestrol acetate).
• High unmet need for targeted therapies addressing metabolic pathways.
• Underdiagnosis and undertreatment in low-resource settings.
Leading Players
Prominent companies include Pfizer Inc., Novartis AG, Merck & Co., Bristol Myers Squibb, Teva Pharmaceuticals, Fresenius Kabi, Nestlé Health Science, Mylan N.V., Hikma Pharmaceuticals, and Kyowa Kirin Co., Ltd.
Segmentation Analysis
The Cancer Anorexia Market can be segmented as follows:
• By Therapy Type
o Pharmacological Interventions
Appetite Stimulants (Megestrol Acetate, Corticosteroids)
Metabolic Modulators (Anti-inflammatory Agents, Ghrelin Mimetics)
o Nutritional Support & Supplements
o Psychological & Behavioral Interventions
o Multimodal Approaches
• By Cancer Type
o Lung Cancer
o Gastrointestinal Cancers
o Pancreatic Cancer
o Head & Neck Cancer
o Others (Breast, Hematologic Malignancies)
• By End Use
o Hospitals & Oncology Centers
o Specialty Clinics
o Palliative & Hospice Care Facilities
o Research & Academic Institutes
Segmentation Summary: While pharmacological interventions dominate current use, the fastest growth is in multimodal care approaches, combining drug therapy, nutritional interventions, and psychological support.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71597/cancer-anorexia-market
Regional Analysis
• North America
Largest market, driven by strong oncology infrastructure, high prevalence of advanced cancer cases, and FDA-backed appetite stimulant approvals. The U.S. leads in adoption of multimodal cachexia management.
• Europe
Significant presence supported by EMA approvals, robust palliative care frameworks, and national cancer care guidelines. Germany, France, and the UK are key contributors.
• Asia-Pacific (APAC)
Expected to record the fastest CAGR through 2034, supported by rising cancer burden, improving healthcare access, and growing demand for palliative care in China, Japan, and India.
• Middle East & Africa
Moderate growth, with GCC countries expanding oncology and palliative care services, while broader Africa faces infrastructure challenges.
• Latin America
Brazil and Mexico dominate, though affordability of novel drugs remains a barrier in several markets.
Regional Summary: North America and Europe dominate today's market, while APAC is projected to grow fastest, reflecting the region's rising cancer prevalence and increasing investment in supportive oncology services.
Market Dynamics
Growth Drivers
• Expansion of real-world evidence (RWE) programs for supportive oncology.
• Increasing pharma investment in ghrelin mimetics and based therapies.
• Strong advocacy for integrating cachexia care into cancer treatment guidelines.
• Growth of telehealth and digital nutrition monitoring platforms.
Challenges
• Limited drug development success due to complex cachexia biology.
• Variability in patient response to appetite stimulants.
• Low physician awareness in emerging markets.
• Lack of reimbursement for supportive care therapies in some regions.
Emerging Trends
• Development of ghrelin receptor agonists and myostatin inhibitors.
• Integration of AI-driven nutrition monitoring and predictive analytics.
• Increasing adoption of personalized nutrition and precision supportive care.
• Expansion of based drug research.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71597
Competitor Analysis
Major Players
• Pfizer Inc.
• Novartis AG
• Merck & Co.
• Bristol Myers Squibb
• Teva Pharmaceuticals
• Fresenius Kabi
• Nestlé Health Science
• Mylan N.V.
• Hikma Pharmaceuticals
• Kyowa Kirin Co., Ltd.
Competitive Landscape
The market is moderately fragmented, with Pfizer, Novartis, and Merck leading pharmacological interventions, while Nestlé Health Science and Fresenius Kabi dominate nutritional solutions. Companies are pursuing strategies including orphan drug designations, partnerships with palliative care networks, and R&D in ghrelin-based drugs.
Conclusion
The Cancer Anorexia Market is projected to grow from USD 1.9 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 6.3%. Rising global cancer prevalence, innovation in pharmacological and nutritional interventions, and greater focus on palliative care will fuel market expansion.
Key Takeaways:
• Market to reach USD 3.5 billion by 2034, at 6.3% CAGR.
• Pharmacological interventions dominate, but multimodal supportive care is expanding rapidly.
• North America and Europe lead, while APAC is the fastest-growing region.
• Competitive dynamics shaped by pharma innovation, nutrition leaders, and rare disease research collaborations.
The next decade will mark a transformative phase in supportive oncology, as novel drugs, precision nutrition, and integrated care models improve outcomes for patients with cancer anorexia worldwide.
This report is also available in the following languages : Japanese (がん拒食症市場), Korean (암 식욕 부진 시장), Chinese (癌症厌食症市场), French (Marché de l'anorexie cancéreuse), German (Markt für Krebs-Magersucht), and Italian (Mercato dell'anoressia e del cancro), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71597/cancer-anorexia-market#request-a-sample
Our More Reports:
Lipodystrophy Market
https://exactitudeconsultancy.com/reports/71998/lipodystrophy-market
Metabolic Acidosis Market
https://exactitudeconsultancy.com/reports/71999/metabolic-acidosis-market
Nephrotic Syndrome Market
https://exactitudeconsultancy.com/reports/72000/nephrotic-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034 here
News-ID: 4171839 • Views: …
More Releases from Exactitude Consultancy

Viral Vector Manufacturing Market to Surge to USD 43.04 Billion by 2034, Growing …
Introduction
The healthcare industry is entering a transformative era where precision therapies are reshaping how we treat diseases. Among the most groundbreaking innovations, viral vectors have emerged as critical enablers of gene and cell therapies. These engineered viruses act as vehicles to deliver therapeutic genetic material directly into patients' cells, making them indispensable for modern medicine. From treating rare genetic disorders to powering revolutionary CAR-T cell therapies in oncology, viral vectors…

Veterinary Vaccines Market to Reach USD 20.65 Billion by 2034, Growing at 6.4% C …
Introduction
Animal health is a cornerstone of global food security, sustainable agriculture, and public health. With rising concerns over zoonotic diseases, antimicrobial resistance, and livestock productivity, the role of veterinary vaccines has never been more critical. These vaccines not only protect animal populations from infectious diseases but also indirectly safeguard humans by preventing disease transmission from animals.
In 2024, the global Veterinary Vaccines Market is valued at USD 11.25 billion and is…

Intravenous Immunoglobulin (IVIG) Market to Reach USD 27.1 Billion by 2034, Grow …
Introduction
In recent years, the healthcare industry has seen significant progress in therapies targeting immune system disorders and rare diseases. At the forefront of these therapies is Intravenous Immunoglobulin (IVIG) - a plasma-derived product containing antibodies that play a crucial role in strengthening or modulating immune response. IVIG is widely used in treating primary and secondary immunodeficiency disorders, autoimmune diseases, neurological disorders, and hematological conditions.
With the rising prevalence of chronic illnesses,…

Lipid Nanoparticle Manufacturing Market to Reach USD 2.48 Billion by 2034, Growi …
Introduction
The pharmaceutical and biotechnology industries are undergoing a paradigm shift driven by the success of mRNA vaccines and the growing promise of gene therapies. At the heart of these breakthroughs are lipid nanoparticles (LNPs) - tiny, lipid-based carriers that safely deliver nucleic acids like mRNA, siRNA, and DNA into target cells. LNPs are now recognized as the gold standard for nucleic acid delivery, fueling advancements in infectious disease prevention, oncology,…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…